Fmr LLC Has $142.12 Million Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

FMR LLC lessened its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,817,699 shares of the company's stock after selling 18,341 shares during the period. FMR LLC owned 9.63% of Immunocore worth $142,122,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC lifted its stake in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. XTX Topco Ltd boosted its holdings in Immunocore by 72.9% during the 3rd quarter. XTX Topco Ltd now owns 15,459 shares of the company's stock valued at $481,000 after acquiring an additional 6,516 shares during the period. Assetmark Inc. grew its position in Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company's stock valued at $949,000 after acquiring an additional 1,616 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after purchasing an additional 420 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

Immunocore stock traded up $0.54 during trading hours on Friday, hitting $28.41. 189,741 shares of the company traded hands, compared to its average volume of 440,167. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $62.74. The firm has a market cap of $1.42 billion, a P/E ratio of -29.90 and a beta of 0.75. The firm's 50-day simple moving average is $28.74 and its two-hundred day simple moving average is $30.40. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Analyst Ratings Changes

Several brokerages have weighed in on IMCR. Mizuho cut their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. JPMorgan Chase & Co. lowered their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday. Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.73.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the company's stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now owns 2,144,060 shares in the company, valued at $63,721,463.20. This represents a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 9.10% of the stock is currently owned by insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.